Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and PD of TAK-988 in Healthy Subjects
NCT04082481Phase 1Withdrawn
- Sponsor
- Takeda
- Start
- Nov 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-988 in narcolepsy (5 arms), sponsored by Takeda. Primary endpoints: Number of Participants Reporting one or More Treatment-emergent Adverse Events, Number of Participants With at Least one Markedly Abnormal Value (MAV) for Laboratory Values and 2 more. Planned start Nov 2021; status: withdrawn.
02
Drugs
TAK-988
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NCT04082481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04082481.